PI3K/Akt/mTOR signaling pathway in cancer stem cells.


Journal

Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 24 04 2022
revised: 21 06 2022
accepted: 29 06 2022
pubmed: 18 7 2022
medline: 26 10 2022
entrez: 17 7 2022
Statut: ppublish

Résumé

Cancer stem cells (CSCs) as a small subpopulation in tumor bulk are believed to initiate tumor formation and are responsible for the resistance to cancer therapy. The proliferation and differentiation of CSCs result in heterogeneity in a tumor which increases the chance of tumor survival and invasion. Many signaling pathways are abnormally activated or repressed in CSCs. Understanding these pathways and the metabolisms in CSCs may help targeted therapy in drug-resistant tumors. The PI3K/Akt/mTOR pathway is one of the major signaling pathways in CSCs involved in the maintenance of stemness, proliferation, differentiation, epithelial to mesenchymal transition (EMT), migration, and autophagy. Thus, suppressing the PI3K/Akt/mTOR pathway with inhibitors might be a promising strategy for targeted cancer therapy. Although the pathway is well-recognized and reviewed in tumor bulks, the functions in CSCs have not been well focused. Here, we reviewed the PI3K/Akt/mTOR signaling pathway and its functions in CSCs and addressed the potential therapeutic applications in drug-resistant tumors.

Identifiants

pubmed: 35843034
pii: S0344-0338(22)00254-0
doi: 10.1016/j.prp.2022.154010
pii:
doi:

Substances chimiques

Phosphatidylinositol 3-Kinases EC 2.7.1.-
Proto-Oncogene Proteins c-akt EC 2.7.11.1
TOR Serine-Threonine Kinases EC 2.7.11.1
MTOR protein, human EC 2.7.1.1

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

154010

Informations de copyright

Copyright © 2022 Elsevier GmbH. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare no conflict of interest.

Auteurs

Mohsen Karami Fath (M)

Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.

Menooa Ebrahimi (M)

Shahid Babai Faculty of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.

Ehsan Nourbakhsh (E)

Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Ahmad Zia Hazara (A)

Department of Immunology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Ali Mirzaei (A)

Faculty of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran.

Saba Shafieyari (S)

Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Azadeh Salehi (A)

Faculty of Pharmacy, Islamic Azad University of Tehran Branch, Tehran, Iran.

Mahsa Hoseinzadeh (M)

Department of Biological Sciences and Technologies, Islamic Azad University of Jahrom, Fars, Iran.

Zahra Payandeh (Z)

Department of Medical Biochemistry and Biophysics, Division Medical Inflammation Research, Karolinska Institute, Sweden.

Ghasem Barati (G)

Stem Cell Technology Research Center, Tehran, Iran. Electronic address: m.gh.barati@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH